Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: April 7, 2003
Last updated: July 18, 2013
Last verified: July 2013